1. Introduction {#sec1}
===============

*Acanthamoeba* keratitis (AK) is a very painful, serious corneal infection caused by free-living pathogenic protozoans of the genus *Acanthamoeba* ([@bib22], [@bib29]). *Acanthamoeba* species are ubiquitous, free-living protozoa that exist as motile trophozoites and dormant cysts in many environments, including swimming pools, hot tubs, lakes, soil, dust and drinking fountains ([@bib3]). The trophozoite stage of *Acanthamoeba* feeds on organic particles and microbes and divides mitotically under optimal condition. With exposure to harsh conditions or during a period of stress, the cells can be transformed into double-walled cysts. The inner wall of the cyst possesses cellulose and the outer wall consists of proteins and polysaccharides. During encystation, the largest increases in resistance are observed.

An increasing number of cases of severe ocular inflammation and visual loss have been caused by *Acanthamoeba* infection in the past two decades. This increased prevalence has been linked to the increasing use of contact lenses ([@bib3], [@bib4], [@bib2], [@bib1]). Clinical cases of AK are largely restricted to contact lens wearers who have experienced some sort of trauma to their corneal epithelium ([@bib6], [@bib26], [@bib28], [@bib24]). Due to difficulty in early diagnosis and poor response to most antibiotics, therapeutic penetrating keratoplasty is often used to try to eradicate the pathogen in uncontrolled disease. If it is not diagnosed early and treated aggressively, extensive ocular damage include a ring-like corneal infiltrate, epithelial destruction, and disproportionately severe ocular pain, could occur and enucleation may be required ([@bib2]).

The first two AK cases in Taiwan were reported in 1988, corneal biopsy yielded confirmative diagnosis ([@bib7]). Medical records reviewed by all patients with clinically diagnosed microbial keratitis presenting at the National Taiwan University Hospital from January 1992 to December 2001, indicated that 4.4% of cases of microbial keratitis were caused by *Acanthamoeba* species ([@bib10]). Currently, the treatment regimen in Taiwan involves hourly drug applications for prolonged periods ([@bib13], [@bib23], [@bib29]). Of these drugs, PHMB is a membrane-active agent with broad-spectrum antimicrobial efficacy that has been used as an antiseptic in infective keratitis ([@bib13], [@bib23], [@bib9], [@bib25]), swimming pool sanitization, and the treatment of cooling systems ([@bib17]). Preparations of PHMB are mixtures of polymeric biguanides with an approximate molecular weight range of 400--8000. The structure of PHMB is as follows: \[---(CH2)6.NH.C(000000000000 000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000 000000000000NH).NH.C(NH).NH---\]n, where n = 2--40, with an approximate molecular weight range of 400--8000. In previous studies on prokaryotic cells, PHMB was shown to interact with cytoplasmic membranes to cause lethal action, nonspecific alterations in membrane integrity, loss of LPS, and loss of function in membrane proteins ([@bib4], [@bib5], [@bib12]). PHMB has also been shown to interfere with prokaryotic cell functions by binding to nucleotides ([@bib1]), and Chindera et al. observed that PHMB not only disrupt the microbial membrane but also arrests cell division and the condensation of chromosomes in treated bacteria species ([@bib8]).

PHMB is further believed to cause the production of large quantities of phosphorus, which accumulate in the nuclei of *A. castellanii* cells as a result of reduced permeability and protein coagulation or the aggregation of phospholipids ([@bib15]). Trophozoites have been reported to absorb more biguanides than do cysts. Complex PHMB-nucleotide formations have been observed near the cell wall and nuclei following drug uptake by *Acanthamoeba*. Nonetheless, clinical outcomes tend to be poor, particularly in cases involving drug-resistant/tolerant strains. The mechanism underlying the resistance to PHMB by *Acanthamoeba* cells has yet to be elucidated for overcoming infection caused by these PHMB-resistant/tolerant strains.

To gain a deeper understanding of the mechanism underlying the first step of resistance to PHMB in *Acanthamoeba*, we established an RNA-seq database for *Acanthamoeba*, including the non-pathogenic ATCC strain and the highly PHMB-tolerant *Acanthamoeba castellanii* strain, NCKH_D ([@bib14]). In our previous study, we have shown that *A. castellanii* clinical isolates NCKH_B and NCKH_D have higher tolerance toward PHMB than does the standard strain, ATCC 30010 ([@bib14]). These two isolates differ in their response to PHMB stress: NCKH_B transforms into a pseudocyst to escape the drug, but NCKH_D does not. Especially, NCKH_D is collected from the combinational drug therapy failed patient. Therefore, NCKH_D utilized an alternative drug tolerance strategy rather than transform into pseudocyst/cyst.

In this study, we try to reveal the molecular mechanism of the PHMB resistance in NCKH_D trophozoites. Furthermore, we found that the mRNA expression level of the disulfideisomerase domain containing protein (PDI) had risen rapidly in surviving cells of the NCKH_D strain but not in the ATCC standard strain during PHMB treatment. After PDI-specific silencing, NCKH_D was found to be more vulnerable to PHMB treatment. The results of this study will help to characterize the potential PHMB resistance mechanisms of *Acanthamoeba* and will aid in the development of a more effective treatment regimen for AK.

2. Materials and methods {#sec2}
========================

2.1. Culture of *Acanthamoeba* protozoa {#sec2.1}
---------------------------------------

*Acanthamoeba* species are axenically cultured in a protease peptone-yeast extract-glucose (PYG) medium, pH 6.5, at 28 °C in cell culture flasks. Trophozoites are harvested at the logarithmic growth phase after cultivation for 3--5 days. The clinical isolates were isolated from the corneal ulcers of patients who were diagnosed with AK in the Cheng Kung University Hospital ([@bib21]), including the high PHMB tolerance pathogenic *Acanthamoeba castellanii* isolates NCKU_D which is used in this study ([@bib14]).

2.2. Growth curves and survival rate {#sec2.2}
------------------------------------

Detached cells will be centrifuged and the pellet will be suspended in a 0.5% trypan blue solution in sterile PBS for 1 min. Cells will be then counted in a Neubauer hemocytometer chamber, and the stained cells will be considered dead. Cell counting will be performed under a light microscope in the duration to get the numbers of alive and dead cells which will be differentiated with trypan blue dye exclusion viability method. The number of stained cells will be subtracted from the total, indicating the death ratio in each interaction condition and time.

2.3. Drug treatment {#sec2.3}
-------------------

PHMB will be preparation in different concentration in Page\'s amoeba saline (PAS). To further clarify the appropriate amount of cells, drug concentration and duration of drug experiment; we will add the counted cells in drug solution and shake by 100 rpm.

2.4. Total RNA isolation and cDNA synthesis {#sec2.4}
-------------------------------------------

We collected the RNA samples from the non-pathogenic isolate ATCC 30010 and the pathogenic *Acanthamoeba castellanii* isolates NCKU_D trophozoites. Pellet the cells by centrifugation, lyse the pellet of *Acanthamoeba* with TRIzol^®^(Invitrogen), add 100% Ethanol (Merck) as 1:1 vol, mix it well by vortexing. Extract the RNA by Direct-zol™ RNA MiniPrep kit (Zymo Research). RNA was stored at −70 °C. The entire concentration and A260/A280 ratio of mRNA were measured with ND-1000 (NanoDrop). High Capacity cDNA Reverse Transcription Kits (Applied Biosystems) were used in this study.

2.5. High-throughput RNA sequence reads collection {#sec2.5}
--------------------------------------------------

The RNA samples from the untreated/PHMB treated *A. castellanii* ATCC 30010 and clinical isolates NCKH_D were used for generating sequence reads with Illumina platform, by which more than 21 million of sequence reads. The samples were also used for reverse transcription PCR validation.

2.6. Reverse transcription PCR {#sec2.6}
------------------------------

One-step reverse transcription PCR was performed with SuperScript™ One-Step RT-PCR with Platinum^®^ Taq kit (Invitrogen) to investigate the gene expression of *Acanthamoeba*. All of the cDNA was synthesized from 1 μg of total RNA of *Acanthamoeba*. RT-PCR products were separated on the EtBr-stained gel after electrophoresis in 1.0--1.2% agarose. Primers were listed in [Table 1](#tbl1){ref-type="table"}.

2.7. Gene silencing methodology {#sec2.7}
-------------------------------

Small interfering RNA (siRNA) targeting on the 1265th to 1283rd nucleotide in the exon coding region of the PDI (ACA1_189420) gene of *Acanthamoeba* was designed and synthesized by Dharmacon (GE Healthcare Dharmacon Inc.), based on the cDNA sequence of the PDI gene. The sense and the antisense sequences are CCAAGAAGCCGGAGAACUAUU and 5′-PUAGUUCUCCGGCUUCUUGGUU. The siRNA was transfected to *Acanthamoeba* trophozoites as described in a previous study ([@bib16]). As a negative control, siRNA with a scrambled sequence (Dharmacon) absent in *Acanthamoeba* was used.

3. Results {#sec3}
==========

To characterize the potential PHMB resistance mechanisms of *Acanthamoeba* and to develop a more effective treatment for AK, we isolated the clinical strains NCKH_D with high PHMB tolerance and created the platforms for screening and elucidating the efficacy of treatment ([@bib14]). To confirm that NCKH_D does not depend on transforming to a cyst to escape the drug, we used a differential interference contrast microscope to observe the morphology of NCKH_D. The result clearly indicates that NCKH_D did not transform to cyst during the 6 h PHMB treatment ([Video 1](#mmc1){ref-type="supplementary-material"}). We proposed that Acanthamoeba could produce the stress proteins and regulate certain genes for responding to PHMB treatments. In this study, we established the RNA datasets of strains including NCKH_D and the standard strain, ATCC 30010, for examining the genes associated with PHMB resistance.

Supplementary video related to this article can be found at [http://dx.doi.org/10.1016/j.ijpddr.2016.11.001](10.1016/j.ijpddr.2016.11.001){#intref0010}.

The following is the supplementary data related to this article:Video 1The long-term observation of *Acanthamoeba* NCKH_D trophozoites during the 6 h PHMB treatment. Images were taken every 30 min by using a differential interference contrast microscope and the analysis is uses for the software of Cell^R^.Video 1

3.1. The discovery of PDI by comparative analysis of RNA-seq {#sec3.1}
------------------------------------------------------------

We analysed the RNA-seq data which were collected from treated and non-treated *Acanthamoeba* cells, with the software package edgeR (empirical analysis of DGE in R), which is part of the Bioconductor project ([@bib11], [@bib27]). The differential gene expression results from the comparative analysis are shown in [Table 2](#tbl2){ref-type="table"}. After combining the differential gene expression results from RNA-seq databases, we noticed that a special gene, the disulfideisomerase domain containing protein (PDI, ACA1_189420), is up-regulated during PHMB treatment in NCKH_D but down-regulated during PHMB treatment in ATCC 30010.

3.2. The validation of PDI expression {#sec3.2}
-------------------------------------

From the comparative analysis of RNA-seq, we found that not only one isoform of PDIs, ACA1_189420, is upregulated during the PHMB-treated experiments but also three isoforms of PDI in the NCBI gene database, including ACA1_149830, ACA1_374090, and ACA1_374120, were up-regulated. To confirm the expression patterns of the PDI isoforms we analysed the RNA samples which were not only previous samples for establishing the database but also those repeated by reverse transcription PCR. The transcriptional expression patterns of the PDI proteins are shown in [Fig. 1](#fig1){ref-type="fig"}A and the quantified the expression patterns of ACA1_189420 are shown in [Fig. 1](#fig1){ref-type="fig"}B. Only the ACA1_189420 in surviving cells of the NCKH_D, a highly PHMB-tolerated isolate strain associated with keratitis infection, increased rapidly compared to the ATCC standard strain, and the three other *A. castellanii* isolates, NCKH_A, C, and P, which were collected from patients with PHMB treatment successes ([Fig. 1](#fig1){ref-type="fig"}C).

3.3. PDI (ACA1_189420) functional domain prediction {#sec3.3}
---------------------------------------------------

To understand the functions of PDI ACA1_189420, we predicted its functional domains via the NCBI Conserved Domain Search website (<http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi>). From the analysed prediction, there are two Thioredoxin-like superfamily domains in ACA1_189420 ([Fig. 1](#fig1){ref-type="fig"}D). Thioredoxins are proteins that act as antioxidants. Therefore, we proposed that PDI (ACA1_189420) may be involved in oxidative protein folding in the endoplasmic reticulum by acting as a catalyst and folding assistant.

3.4. The expression level of thioredoxindisulfide reductase (ACA1_398900) does not change during PHMB treatment {#sec3.4}
---------------------------------------------------------------------------------------------------------------

The proteins that act as antioxidants are usually maintained in their reduced form at steady state. So we were curious about the expression pattern of Thioredoxindisulfide reductase (ACA1_398900), which is the enzyme used to reduce Thioredoxindisulfide in Acanthamoebal cells during the PHMB treatment. From the results shown in [Fig. 2](#fig2){ref-type="fig"}A and B, the transcriptional expression level of ACA1_398900 does not change after PHMB treatment.

3.5. PDI (ACA1_189420) is important for NCKH_D PHMB tolerance ability {#sec3.5}
---------------------------------------------------------------------

For elucidating the importance of PDI ACA1_189420 in the PHMB tolerance of NCKH_D, we knocked down the gene expression and used the PHMB treatment again. After PDI ACA1_189420-specific siRNA treatment, we found NCKH_D to be more vulnerable to PHMB ([Fig. 3](#fig3){ref-type="fig"}). The result revealed that PDI is an important gene for the PHMB tolerance ability.

3.6. PDI is not a general stress protein {#sec3.6}
----------------------------------------

To prove that ACA1_189420 is a general stress or a PHMB specific induced response protein, we tested physical and chemical stresses, such as heat shock and H~2~O~2~ treatments.

In heat shock experiments, we found that NCKH_D is more tolerant to high-temperature treatment than the ATCC standard strain 30010 ([Fig. 4](#fig4){ref-type="fig"}A). These results indicate that the PDI (ACA1_189420) expression of 30010 and NCKH_D is both downregulated, which means PDI is not important for the high-temperature tolerance ability of NCKH_D ([Fig. 4](#fig4){ref-type="fig"}B). In H~2~O~2~ treatment experiments, NCKH_D was also more tolerant to hydrogen peroxide treatment than 30010, but the PDI expression of NCKH_D had no specific change ([Fig. 5](#fig5){ref-type="fig"}A and B). Thus, we have shown that PDI (ACA1_189420) is a PHMB induced stress protein but not a general stress protein.

4. Discussion {#sec4}
=============

The broad-spectrum antimicrobial polymer PHMB kills bacteria, fungi, parasites and certain viruses. Presently, AK treatment involves hourly applications of PHMB over a prolonged period; however, even this aggressive approach is unable to ensure anything other than a poor prognosis. Further, the treatment is not entirely effective against all strains/isolates. Our previous work presented a PHMB highly tolerant isolate, NCKH_D, which does not depend on transforming to a cyst to escape the drug ([@bib14]). However, the action and resistance mechanisms of PHMB in *Acanthamoeba* cells are still not clear. Knowledge of these mechanisms could be used to progress the current treatment for more effective use against the infection.

Based on the experimental results of the present study, we have for the first time provided solid evidence that PDI (ACA1_189420) is a PHMB resistance associated gene in *Acanthamoeba*. There are two Thioredoxin-like superfamily domains in PDI (ACA1_189420). Thioredoxin (Trx), an important factor for protein dithiol/disulfide homeostasis and is conserved from bacteria to man. However, the role of the Thioredoxin reductase (TrxR)/Trx system is still poorly understood in *Acanthamoeba*. In other protists, there are alternative factors in the Trx system that have been reported as drug targets for parasites. In 2007, Leitsch et al. found that the anti-oxidative enzyme, TrxR, could reduce metronidazole and other nitro compounds in *Entamoeba histolytica* ([@bib19]). TrxR has also been found to reduce metronidazole and other nitro-heterocyclic drugs in *Trichomonas vaginalis* ([@bib18]). In *Giardia lamblia*, TrxR has been suggested to assist as a drug target ([@bib20]).

In this study, we have elucidated the associated gene and possible mechanism of PHMB resistance, as described here with a highly PHMB-tolerant strain of *Acanthamoeba*. This study also provides novel insight for dissecting the PHMB resistant mechanisms in *Acanthamoeba* and possible improvements for PHMB treatment of *Acanthamoeba* keratitis.

5. Conclusion {#sec5}
=============

These results described above show that PDI (ACA1_189420) is an important gene for PHMB tolerance ability in highly PHMB-tolerant *Acanthamoeba*.
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![**The expression level of PDI genes in clinical isolate NCKH_D and ATCC 30010 with or without PHMB treatment**. (A) and (C) Reverse transcription PCR analysis. The 18S rRNA expression is used as a control. (D) Functional domain prediction of PDI gene, ACA1_189420.](gr1){#fig1}

![**The expression level of thioredoxindisulfide reductase in clinical isolate NCKH_D and ATCC 30010 with or without PHMB treatment**. (A) and (B) Reverse transcription PCR analysis. The 18S rRNA expression is used as a control.](gr2){#fig2}

![**Effects of ACA1_189420 silencing in the NCKH_D strain during the progress of PHMB treatment**. \*\*, the means are significantly different at a P value of \<0.01; \*, the means are significantly different at a P value of \<0.05 by Student\'s *t*-test.](gr3){#fig3}

![**Effects of the *Acanthamoeba* strains during the heat shock treatment**. (A) Survival rate of *Acanthamoeba* strains during the 40 °C shock. (B) Reverse transcription PCR analysis of the PDI gene, ACA1_189420, expression level in clinical isolate NCKH_D and ATCC 30010 with or without 40 °C heat shock. The 18S rRNA expression is used as a control.](gr4){#fig4}

![**The expression level of ACA1_189420 in *Acanthamoeba* strains during the H**~**2**~**O**~**2**~**treatment**. (A) The light observation for effect imaging of the addition of H~2~O~2~ to the live *Acanthamoeba* strains. (B) Reverse transcription PCR analysis of the PDI gene, ACA1_189420, expression level in clinical isolate NCKH_D and ATCC 30010 with or without H~2~O~2~ treatment. The 18S rRNA expression is used as a control.](gr5){#fig5}

###### 

Primer list used for PCR and reverse transcription PCR reactions.

Table 1

  ------------------------------------------------------------------------------------------------------------------
  Target region   Primers name                Primer sequence (5′ -- 3′)   Amplicon (bp)   
  --------------- --------------------------- ---------------------------- --------------- -------------------------
  18s rDNA        AcantF900                   CCCAGATCGTTTACCGTGAA         180             Qvarnstrom et al., 2006

  AcantR1100      TAAATATTAATGCCCCCAACTATCC                                                

  PDI gene\                                   ACTTCGATGAGCACACTGCC         641             
  ACA1_189420                                                                              

                  AACGCCAGAGTAGTCCCTCA                                                     

  PDI gene\                                   CAAGGCCGACCTCTTTGACT         621             
  ACA1_374120                                                                              

                  CTGCCGAGCTCATAGTCCTG                                                     

  PDI gene\                                   GACGTGTGGAACCCCATCAA         449             
  ACA1_374090                                                                              

                  TTGTCATTGTCCGCGAAACG                                                     

  PDI gene\                                   TCGAAGACTTCACCGCCTTC         481             
  ACA1_149830                                                                              

                  AGCTCGTCCTTCTTTTCGGG                                                     

  TrXR\                                       AGTACACAGAATGGTCATCGT        681bp           
  ACA1_398900                                                                              

                  TTGATCTTGAGGCCTGTGAC                                                     
  ------------------------------------------------------------------------------------------------------------------

###### 

Differential gene expression statistics from RNA-Seq.

Table 2

  Effective transcripts                 DE transcripts[a](#tbl2fna){ref-type="table-fn"}                          
  ------------------------------------- -------------------------------------------------- ---------------------- --------
  30010 non-treat VS treated PHMB 3HR   13,642                                             71                     0.47%
  D, non-treat VS treated PHMB 3HR      12,139                                             525                    3.50%
  D vs 30010, non-treat                 13,583                                             3260                   21.76%
  Total references                      14,980                                             **(FDR** ≤ **0.05)**   

The effective transcripts defined as the count sum of two libraries for a transcript ≥1.
